Dr. Wierda Discusses Trials of Novel Combinations in CLL

William G. Wierda, MD, PhD
Published: Saturday, Oct 07, 2017



William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia (CLL).

The combination of ibrutinib (Imbruvica), cyclophosphamide, fludarabine, and obinutuzumab (Gazyva) is currently being tested at MD Anderson in younger patients with a mutated immunoglobulin heavy chain variable gene.

Additionally, a study of ibrutinib plus venetoclax (Venclexta) is currently ongoing, and data on that combination will be presented at this year’s ASH Annual Meeting.
 


William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia (CLL).

The combination of ibrutinib (Imbruvica), cyclophosphamide, fludarabine, and obinutuzumab (Gazyva) is currently being tested at MD Anderson in younger patients with a mutated immunoglobulin heavy chain variable gene.

Additionally, a study of ibrutinib plus venetoclax (Venclexta) is currently ongoing, and data on that combination will be presented at this year’s ASH Annual Meeting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x